Dasotraline as a Novel DAT/NET Inhibitor for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-concept Trial in Adults
Publication
, Conference
Koblan, K; Hopkins, S; Sarma, K; Jin, F; Goldman, R; Loebel, A; Kollins, S
Published in: NEUROPSYCHOPHARMACOLOGY
December 1, 2014
Duke Scholars
Published In
NEUROPSYCHOPHARMACOLOGY
EISSN
1740-634X
ISSN
0893-133X
Publication Date
December 1, 2014
Volume
39
Start / End Page
S347 / S347
Location
Phoenix, AZ
Publisher
NATURE PUBLISHING GROUP
Conference Name
53rd Annual Meeting of the American-College-of-Neuropsychopharmacology (ACNP)
Related Subject Headings
- Psychiatry
- 5202 Biological psychology
- 3209 Neurosciences
- 17 Psychology and Cognitive Sciences
- 11 Medical and Health Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Koblan, K., Hopkins, S., Sarma, K., Jin, F., Goldman, R., Loebel, A., & Kollins, S. (2014). Dasotraline as a Novel DAT/NET Inhibitor for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-concept Trial in Adults. In NEUROPSYCHOPHARMACOLOGY (Vol. 39, pp. S347–S347). Phoenix, AZ: NATURE PUBLISHING GROUP.
Koblan, Kenneth, Seth Hopkins, Kaushik Sarma, Fengbin Jin, Robert Goldman, Antony Loebel, and Scott Kollins. “Dasotraline as a Novel DAT/NET Inhibitor for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-concept Trial in Adults.” In NEUROPSYCHOPHARMACOLOGY, 39:S347–S347. NATURE PUBLISHING GROUP, 2014.
Koblan K, Hopkins S, Sarma K, Jin F, Goldman R, Loebel A, et al. Dasotraline as a Novel DAT/NET Inhibitor for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-concept Trial in Adults. In: NEUROPSYCHOPHARMACOLOGY. NATURE PUBLISHING GROUP; 2014. p. S347–S347.
Koblan, Kenneth, et al. “Dasotraline as a Novel DAT/NET Inhibitor for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-concept Trial in Adults.” NEUROPSYCHOPHARMACOLOGY, vol. 39, NATURE PUBLISHING GROUP, 2014, pp. S347–S347.
Koblan K, Hopkins S, Sarma K, Jin F, Goldman R, Loebel A, Kollins S. Dasotraline as a Novel DAT/NET Inhibitor for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-concept Trial in Adults. NEUROPSYCHOPHARMACOLOGY. NATURE PUBLISHING GROUP; 2014. p. S347–S347.
Published In
NEUROPSYCHOPHARMACOLOGY
EISSN
1740-634X
ISSN
0893-133X
Publication Date
December 1, 2014
Volume
39
Start / End Page
S347 / S347
Location
Phoenix, AZ
Publisher
NATURE PUBLISHING GROUP
Conference Name
53rd Annual Meeting of the American-College-of-Neuropsychopharmacology (ACNP)
Related Subject Headings
- Psychiatry
- 5202 Biological psychology
- 3209 Neurosciences
- 17 Psychology and Cognitive Sciences
- 11 Medical and Health Sciences